Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SIK1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SIK1 Recombinant Protein (Active Kinase Domain / Full Length) High purity (>95%), Endotoxin controlled, Sequence Verified. Suitable for enzymatic assays. |
View SIK1 Products |
| Gene Delivery | SIK1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines, cell-based phosphorylation assays, and target validation. |
View SIK1 Products |
| Benchmark Ab | Anti-SIK1 Recombinant Antibody High-affinity positive control for Western Blot, IHC, and IP validation. |
View SIK1 Products |
| Validator | SIK1 siRNA Set Target-specific knockdown verification in tumor or metabolic cell lines. |
View SIK1 Products |
| Related Target A | SIK2 Homologous kinase; crucial for selectivity profiling to prevent off-target toxicity. |
View SIK2 Products |
| Related Target B | SIK3 Homologous kinase; critical counter-screening target for pan-SIK vs. isoform-selective programs. |
View SIK3 Products |
| Related Target C | CRTC1 Direct downstream substrate of SIK1; essential for functional readout assays. |
View CRTC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| SIK Family Selectivity (SIK1 vs. SIK2/3) | Highly purified, active recombinant SIK1, SIK2, and SIK3 proteins available for comparative IC50 profiling. |
| Enzymatic Assay Reproducibility | Batch-to-batch consistency verified by mass spectrometry and strict purity assays (>95% by SDS-PAGE). |
| Lack of Validated Control Antibodies | Sequence-defined recombinant benchmark antibodies ensure robust assay baselines. |
| Target Specificity Verification | Sequence-verified siRNA pools eliminate off-target signaling doubts during phenotypic screening. |
Live SIK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SIK1 therapeutics is intensifying, with major players shifting focus from non-selective kinase inhibitors to highly specific SIK isoform modulators and PROTAC degraders. As first-generation pan-SIK inhibitors reach clinical evaluation—primarily in oncology to reprogram the tumor microenvironment—the next wave of R&D is targeting isoform-specific SIK1 inhibition to treat metabolic disorders (such as gluconeogenesis regulation) and cardiac hypertrophy without causing systemic toxicities associated with SIK3 inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Bristol Myers Squibb, Merck, Biopharma Startups | Solid Tumors (Immunotherapy sensitization), Diabetes | Selectivity Assay (Need SIK1, SIK2, and SIK3 Recombinant Proteins) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Ovarian Cancer, Triple-Negative Breast Cancer (TNBC) | Target Ubiquitination & Degradation Assay (Need Lentivirus for Stable SIK1 Expression) |
| RNA Therapeutics / siRNA | Academic Institutes, Biotech Consortia | Hepatic Gluconeogenesis, Metabolic Syndrome | Knockdown Verification & In Vivo Mimicry (Need SIK1 siRNA & Validation Controls) |